Bone Abstracts

Introduction: Femoral neck fractures and trochanteric fractures are two major types of hip fractures. The BMD changing or hip strength analysis (HSA) of the two type fractures may be different. No research had focused on a large sample of Asian people. This study investigated the differences in BMD and morphologic features of the two type hip fractures of elderly Asian people from QCT.Methods: A total of 279 elderly Chinese patients with hip fractures du...

Low bone formation is considered to be the main feature in osteoporosis associated with cholestatic and end-stage liver diseases. Previous studies have demonstrated the deleterious consequences of retained substances such as lithocholic acid (LCA) and bilirubin (Bil) on osteoblastic cells. These effects are neutralized by ursodeoxycholic acid (UDCA). To gain new insights into cholestatic-induced osteoporosis, we have assessed the differential gene expression of osteoblastic ce...

Safety data on zoledronic acid (ZA) administration for osteoporosis suggest potential kidney toxicity; indeed, it is not indicated in patients with impaired renal function. Patients’ clinical monitoring usually includes glomerular filtration rate (GFR) evaluation; no study addressed the issue of the early kidney injury. We evaluated the early (within 3 months) effect of iv ZA on renal function defining the potential role of AKI biomarkers in unveiling subtle damage.<p...

Fibrodysplasia ossificans progressiva (FOP) is a rare debilitating genetic disease characterized by abnormal progressive heterotopic endochondrial ossification of soft tissues. FOP results from mutations in the intracellular domain of the type I BMP receptor ACVR1 (ALK2) the most common of which is R206H. FOP mutations alter the sensitivity of ACVR1 to Activin A from an antagonist to an agonist. We have previously shown that Activin A is necessary and sufficient for driving he...

Objectives: Differential diagnosis vs. Osteogenesis Imperfecta (OI).Methods: The parents were Moroccan origin, consanguineous. The patient is an 8 year old girl, who was visited for a first time in our hospital in October 2016, presenting a fracture of the left femur, with dramatic bone deformations, with important disability, unable to walk and with growth retardation (weight 15 kg, length: 92 cm). The first registered fracture is at birth, consisting o...

Background: Several short-term studies have been performed in rheumatoid arthritis (RA) reporting a rapid rate of generalized bone loss. Aggressive anti-inflammatory treatment with biologic disease modifying anti-rheumatic drugs (DMARDs) has been shown to reduce the rate of bone loss1. There is a lack of long term follow-up studies.Objectives: To study 10-year changes in generalized bone loss in early RA patients in the biologic treatment era....

Bones’ fracture resistance is achieved in vivo by adaptation to habitual loading. Aged bone can adapt to exercise1 but in female rodents ageing impairs the adaptive response to artificial loading2,3. This inconsistency led us to investigate whether treadmill exercise, sufficiently mild to not itself stimulate new bone formation, could rescue aged bone’s diminished response to artificial loading.Young adult 17-week...

Aim: We explored the hypothesis that idiopathic hypercalciuria (IH) causes increased bone loss in early post-menopausal women.Materials and methods: We studied 41 postmenopausal women with IH. Inclusion criteria: i) recently (<6 months) diagnosed and untreated IH, ii) postmenopausal status >2 years, and iii) normal renal function. Exclusion criteria: i) all causes of hypercalciuria other than IH and ii) use of any medication for osteoporosis 1-ye...

Introduction: Osteocytes play a major role in the bone remodelling unit (BRU). Thus, we hypothesize that mitochondrial bioenergetics impairment and mitochondrial/peroxisomal fatty acid β-oxidation unbalance is a cause of osteocytes metabolic decline during 17β-estradiol (E2) reduction. E2 and a phytochemical substitute, coumestrol (COU) were used (30 mg/kg during 24 h in ovariectomized rats in order to compare bone loss with sham-operated animal...

Objectives: Childhood osteoporosis can be treated with i.v. bisphosphonates in order to improve bone mass and density. The aims of this study were to evaluate the safety and efficacy of 6-monthly zoledronic acid (ZA) in children with osteoporosis.Methods: A retrospective cohort study of 27 patients (16 males and 11 females) were treated with 6-monthly ZA (0.05 mg/kg per dose) for a minimum of 1 year. Seventeen patients were immobile, 4 had steroid-induce...